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Introduction
Juvenile Localized Scleroderma (JLS) and Juvenile
Systemic Sclerosis (JSSc) form a group of rare pediatric
diseases that can lead to significant morbidity. Evidence-
based guidelines are sparse and management is mostly
based on physician’s experience. Consequently, treat-
ment regimens differ throughout Europe. In 2012, a
European initiative called SHARE (Single Hub and
Access point for pediatric Rheumatology in Europe) was
launched to optimize and disseminate diagnostic and
management regimens in Europe for children and young
adults with rheumatic diseases.
Objectives
One of the aims of SHARE was to provide evidence
based recommendations for diagnosis and treatment of
Juvenile Scleroderma.
Methods
Evidence based recommendations were developed using
the European League Against Rheumatism (EULAR)
standard operating procedure. An expert committee was
instituted, consisting of pediatric rheumatologists and
experts in Juvenile Scleroderma. The expert committee
defined search terms for the systematic literature review.
Two independent experts scored articles for validity and
level of evidence. Recommendations derived from the
literature were evaluated by an online survey. Those
with less than 80% agreement during the online survey
were reformulated. Subsequently, all recommendations
were discussed at a consensus meeting using the nom-
inal group technique [Delbeq AL. A group process
model for problem identification and program planning
The Journal of Applied Behavioral Science July 1971 7:
466-492]. Recommendations were accepted if more than
80% agreement was reached.
Results
The literature search yielded 1550 articles for JLS and
8562 for JSSc, of which 52 and 37, respectively (25 for
diagnosis and 27 for treatment of JLS, 21 for diagnosis
and 16 for treatment of JSSc) were considered relevant
and therefore scored for validity and level of evidence.
42 articles (15 for diagnosis and 14 for treatment of JLS,
6 for diagnosis and 7 for treatment of JSSc) were scored
valid and used in the formulation of the recommenda-
tions. 11 recommendations for diagnosis and 7 for
treatment were suggested in the online survey on JLS.
Ten recommendations for diagnosis and 6 for treatment
were accepted with more than 80% agreement after the
consensus meeting. Six recommendations for diagnosis
and 5 for treatment were suggested in the online survey
on JSSc. 6 recommendations for diagnosis and 4 for treat-
ment were accepted with more than 80% agreement after
the consensus meeting. Topics covered for diagnosis and
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and response to therapy, disease severity and damage
assessment, extra-cutaneous involvement (articular,
musculoskeletal, neurological, ophtalmological, dental,
maxillo-facial), topical treatments (medium-dose UVA1
phototherapy, imiquimod) and systemic treatment (corti-
costeroids, metotrexate, mychophenolate mofetil); for JSSc
disease severity and damage assessment, diagnosis of skin
involvement, lung involvement and Raynaud’s phenom-
enon, treatment of skin, lung and vascular involvement
and autologous stem-cell transplantation.
Conclusion
The SHARE initiative provides recommendations for
diagnosis and treatment for Juvenile Scleroderma and
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